Myocardial effects of cyclic AMP phosphodiesterase inhibition are dampened in thyroxine-induced cardiac hypertrophy

Journal of Surgical Research

Volumn 76, Issue 1, 1998, Pages 61-66

  Straznicka, Michaela ^a   Leone Jr , Richard J ^a   Scholz, Peter M ^a   Weiss, Harvey R ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Coronary blood flow; Cyclic AMP; Milrinone; Myocardial function; Myocardial oxygen consumption; Rabbit; Thyroxine

Indexed keywords

CYCLIC AMP; CYCLIC AMP PHOSPHODIESTERASE; MILRINONE; THYROXINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD PRESSURE; BODY WEIGHT; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; ENDOCARDIUM; ENZYME INHIBITION; EPICARDIUM; HEART LEFT VENTRICLE DP-DT; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; MICROSPECTROPHOTOMETRY; NONHUMAN; PRIORITY JOURNAL; RABBIT; THYROTOXICOSIS;

EID: 0031879122     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1997.5292     Document Type: Conference Paper

References (34)

1. Dillman W. H. Biochemical basis of thyroid hormone action in the heart. Am. J. Med. 88:1990;626.
2. Klein I. Thyroid hormone and the cardiovascular system. Am. J. Med. 88:1990;631.
3. Levey G. S. Catecholamine sensitivity, thyroid hormone and the heart. Am. J. Med. 50:1971;413.
4. 22. Circ. Res. 52:1983;272.
5. Morkin E., Flink I. L., Goldman S. Biochemical and physiologic effects of thyroid hormone on cardiac performance. Prog. Cardiovasc. Dis. 25:1983;435.
6. Siehl D., Chua B. H. L., Lautensack-Belser N., Morgan H. E. Faster protein and ribosome synthesis in thyroxine-induced hypertrophy of rat heart. Am. J. Physiol. 248:1985;C309.
7. Klein I., Hong C. Effects of thyroid hormone on cardiac size and myosin content of the heterotopically transplanted rat heart. J. Clin. Invest. 77:1986;1694.
8. Rodriguez E., Weiss H. R., Gonzalez M., Tse J. Effect of isoproterenol on coronary blood flow and signal transduction responses in thyroxine-treated rabbit hearts. J. Mol. Cell. Cardiol. 25:1993;939.
9. Levey G. S. Catecholamine-thyroid interactions and the cardiovascular manifestations of hyperthyroidism. Am. J. Med. 88:1990;642.
10. Liggett S. B., Shah S. D., Cryer P. E. Increased fat and skeletal muscle β-adrenergic receptors but unaltered metabolic and hemodynamic sensitivity to epinephrinein vivo. J. Clin. Invest. 83:1989;803.
11. Beaven M. A., Costa E., Brodie B. B. The turnover of norepinephrine in thyrotoxic and nonthyrotoxic mice. Life Sci. 4:1963;241.
12. Levey G. S. The adrenergic nervous system in hyperthyroidism: Therapeutic role of β-adrenergic blocking drugs. Pharmacol. Ther. C1:1976;431.
13. Coulombe P., Dussault J. H., Letarte J., Simard S. J. Catecholamine metabolism in thyroid diseases. J. Clin. Endocrinol. Metab. 42:1976;125.
14. Chiu W. C., Kedem J., Weiss H. R., Tse J., Cheinberg B. V., Scholz P. M. Milrinone, a cyclic AMP-phosphodiesterase inhibitor, has differential effects on regional myocardial work and oxygen consumption in experimental left ventricular hypertrophy. Cardiovasc. Res. 28:1994;1360.
15. Tse J., Wrenn R. W., Kuo J. F. Thyroxine-induced changes in characteristics and activities of β-adrenergic receptors and adenosine 3′,5′-monophosphate and guanosine 3′,5′-monophosphate systems in the heart may be related to reputed catecholamine supersensitivity in hyperthyroidism. Endocrinology. 107:1980;6.
16. Hohl C. M., Wetzel S., Fertel R. H., Wimsatt D. K., Brierley G. P., Altschuld R. A. Hyperthyroid adult rat cardiomyocytes. Am. J. Physiol. 257:1989;C948.
17. Weiss H. R., Sinha A. K. Regional oxygen saturation of small arteries and veins in the canine myocardium. Circ. Res. 42:1978;119.
18. Zhu N. H., Weiss H. R. Oxy- and carboxyhemoglobin saturation determination in frozen small vessels. Am. J. Physiol. 260:1991;H626.
19. Stoclet J. C., Boulanfer-Saunier C., Lassegue B., Lugnier C. Cyclic nucleotides and calcium regulation in heart and smooth muscle cells. Ann. N.Y. Acad. Sci. 522:1988;106.
20. Ishac E. J., Pennefather J. N., Handberg G. M. Effect of changes in thyroid state on atrial alpha and beta adrenoceptors, adenylate cyclase activity, and the catecholamine levels in the rat. J. Cardiovasc. Pharmacol. 5:1983;396.
21. Dorigo P., Gaion R. M., Belluco P., Mosti L., Borea P. A., Marango I. An analysis of the mechanism of the inotropic action of some milrinone analogues in guinea-pig isolated atria. Br. J. Pharmacol. 104:1991;867.
22. Frangakis C. J., Lanni C., Lasher K. P., Bentley R. G., Farah A. E. The role of cyclic AMP and the dihydropyridine-sensitive channels on the mechanism of action of milrinone. J. Cardiovasc. Pharmacol. 13:1989;915.
23. Weiss H. R., Rodriguez E., Tse J., Scholz P. M. Effect of increased myocardial cyclic GMP induced by cyclic GMP-phosphodiesterase inhibition on oxygen consumption and supply in rabbit hearts. Clin. Exp. Pharmacol. Physiol. 21:1994;607.
24. 2. Am. J. Physiol. 37:1995;H686.
25. Weiss H. R., Tse J. Myocardial metabolic and functional responses to acetylcholine are altered in thyroxine-induced cardiac hypertrophy. Can. J. Physiol. Pharmacol. 73:1995;729.
26. Eliades D., Weiss H. R. Role of β-adrenoceptors in the hypertrophic response to thyroxine. J. Cardiovasc. Pharmacol. 14:1989;58.
27. 2. Am. J. Physiol. 246:1984;H374.
28. Oppenheimer J. H., Schwartz H. L., Mariash C. N., Kinlaw W. B., Wong N. C. W., Freake H. C. Advances in our understanding of thyroid hormone action at the cellular level. Endocrinol. Rev. 8:1987;288.
29. Sanford C. F., Griffin E. E., Wildenthal K. Synthesis and degradation of myocardial protein during the development and regression of thyroxine-induced cardiac hypertrophy in rats. Circ. Res. 43:1978;688.
30. Merillon J. P., Passa P. H., Chastre J., Wolf A., Gourgon R. Left ventricular function and hyperthyroidism. Br. Heart J. 46:1981;137.
31. Klein I. Thyroxine-induced cardiac hypertrophy: Time course of development and inhibition by propanolol. Endocrinology. 123:1988;203.
32. 2. Life. Sci. 53:1993;1847.
33. Movsesian M. A., Smith C. J., Krall J., Bristow R., Manganiello V. C. Sarcoplasmic reticulum-associated cyclic adenosine 5′-mono-phosphate phosphodiesterase activity in normal and failing human hearts. J. Clin. Invest. 88:1991;15.
34. Bethke T., Klimkiewicz A., Kohl C. Effect of isomazole on force and contraction and phosphodiesterase isoenzymes I-IV in non-failing and failing human hearts. J. Cardiovasc. Pharmacol. 18:1991;386.